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ABSTRACT 25 
Study Objectives 26 
The rise in obesity has been paralleled by a decline in sleep duration in epidemiological 27 
studies. However, the potential mechanisms linking energy balance and the sleep/wake cycle 28 
are not well understood. We aimed to examine the effects of manipulating energy balance on 29 
the sleep/wake cycle. 30 
Methods 31 
Twelve healthy normal weight men were housed in a Clinical Research Facility and studied 32 
at three time-points: baseline, after energy balance was disrupted by two days of caloric 33 
restriction to 10% of energy requirements, and after energy balance was restored by two days 34 
of ad libitum/free feeding. Sleep architecture, duration of sleep stages, and sleep-associated 35 
respiratory parameters were measured by polysomnography. 36 
Results 37 
Two days of caloric restriction significantly increased the duration of deep (stage 4) sleep 38 
(16.8 to 21.7% of total sleep time; p=0.03); an effect which was entirely reversed upon free 39 
feeding (p=0.01). While the apnea-hypopnea index stayed within the reference range (<5 40 
events per hour), it decreased significantly from caloric restriction to free feeding (p=0.03). 41 
Caloric restriction was associated with a marked fall in leptin (p<0.001) and insulin levels 42 
(p=0.002). The fall in orexin levels from baseline to caloric restriction correlated positively 43 
with duration of stage 4 sleep (Spearman rho=0.83, p=0.01) and negatively with the number 44 
of awakenings in caloric restriction (Spearman rho=-0.79, p=0.01). 45 
4 
Conclusions 46 
We demonstrate that changes in energy homeostasis directly and reversibly impact on the 47 
sleep/wake cycle. These findings provide a mechanistic framework for investigating the 48 
association between sleep duration and obesity risk. 49 
 50 
STATEMENT OF SIGNIFICANCE 51 
Acute manipulation of energy balance without change in body weight impacts on the 52 
sleep/wake cycle by increasing the duration of the deepest stage of sleep, which was 53 
normalized with restoration of energy balance. Our results are in line with a study in the early 54 
1970s in which the duration of slow wave sleep increased after four days of complete 55 
starvation associated with weight loss. Taken together, these studies and previous studies of 56 
sleep deprivation provide a mechanistic framework for investigating the well-recognized 57 
associations between obesity and sleep disorders and between sleep debt and obesity risk. 58 
5 
LIST OF ABBREVIATIONS 59 
AHI, apnea-hypopnea index; ANOVA, analysis of variance; AUC, area under the curve; BL, 60 
baseline; BMI, body mass index; CR, caloric restriction; CSF, cerebrospinal fluid; EEG, 61 
electroencephalographic; FF, free feeding; GH, growth hormone; GHRH, growth hormone-62 
releasing hormone; mRNA, messenger ribonucleic acid; PET, positron emission tomography; 63 
POMS, profile of mood states questionnaire; PSG, polysomnography; REM, rapid eye 64 
movement; SA, sensitivity analysis; SEM, standard error of the mean; SNS, sympathetic 65 
nervous system; SpO2, blood oxygen saturation; SPT, sleep period time; SWS, slow wave 66 
sleep; TIB, time in bed; TSH, thyroid stimulating hormone; TST, total sleep time; WASO, 67 
wake after sleep onset. 68 
6 
INTRODUCTION 69 
The rising prevalence of obesity and associated disorders such as type 2 diabetes is associated 70 
with significant morbidity and mortality and represents a major public health concern. 71 
Reduced levels of physical activity and the increased consumption of highly palatable energy 72 
dense foods are major contributors to the rise in body mass index (BMI). Another factor that 73 
has been associated with an increased risk of obesity is an increase in sleep debt.
1, 2
 Surveys 74 
of secular trends in sleeping habits have reported a marked decrease in sleep duration over 75 
the last 30 years.
3
 Multiple cross-sectional and longitudinal studies have reported a positive 76 
correlation between short sleep duration (by self-report and measured objectively by 77 
actigraphy) and increased susceptibility to obesity.
4
 It is unclear why sleep debt and obesity 78 
risk appear to be associated, but potentially causal mechanisms have been suggested by 79 
experimental clinical studies in which moderate sleep restriction has been shown to reduce 80 
energy expenditure,
5
 increase hunger ratings and food intake,
6, 7
 and decrease insulin 81 
sensitivity.
8, 9
 However, surprisingly little is known about the reverse relationship, namely the 82 
impact of changes in energy balance on the sleep/wake cycle. 83 
To directly examine the effects of manipulating energy balance on the sleep/wake cycle, we 84 
studied 12 normal weight men before and after two days of caloric restriction (CR) to 10% of 85 
their normal energy requirements. CR was followed by a period of free feeding (FF) to allow 86 
for energy homeostasis to be reset. We measured ad libitum food intake to quantify changes 87 
in energy balance during this experimental paradigm. We assessed sleep architecture and 88 
sleep-associated respiratory parameters in the baseline state, after CR, and upon FF using 89 
polysomnography (PSG) which combines overnight electro-encephalographic recording with 90 
measurements of chest wall movements, eye movements, and peripheral oxygen saturation. 91 
We measured fasting levels of peripheral hormones which might mediate the effects of 92 
changes in energy balance on the sleep/wake cycle (leptin, insulin, and total ghrelin) and the 93 
7 
neuropeptide orexin A which plays a critical role in arousal. In response to physiological 94 
stresses such as CR, hypothalamic pathways activate autonomic, neuroendocrine, and 95 
behavioral responses to maintain homeostasis. Therefore, we measured heart rate (autonomic 96 
nervous system activity), the overnight pulsatile secretion of thyroid stimulating hormone 97 
(TSH), growth hormone (GH), and cortisol release, as well as cognitive parameters and 98 
mood-related symptom scores. 99 
8 
RESEARCH DESIGN AND METHODS 100 
The study was approved by the Cambridge local research ethics committee and was 101 
conducted in accordance with the principles of the Declaration of Helsinki. Written informed 102 
consent was received from each participant prior to inclusion in the study. All clinical studies 103 
were conducted at the NIHR-Wellcome Trust Clinical Research Facility, Addenbrooke’s 104 
Hospital, Cambridge, United Kingdom. 105 
We recruited 17 normal weight adult male volunteers (BMI of 20-25 kg/m
2
). After screening, 106 
twelve volunteers satisfied the following inclusion criteria: normal glucose tolerance 107 
measured by a 75-gram oral glucose tolerance test, no evidence of renal, liver or thyroid 108 
disease, average alcohol intake <2 units/day, not participating in an organized exercise 109 
program, not treated with anorectic agents or medications known to affect carbohydrate 110 
and/or lipid metabolism, or blood pressure. Shift workers were excluded from the study and 111 
all participants had a normal sleep/wake pattern as determined by PSG at screening and self-112 
reported quality of sleep scores (Table S1). Weight and height were measured barefoot in 113 
light clothing and BMI calculated (weight in kg/height in meters squared). 114 
Participants were resident on the Clinical Research Facility for the duration of the study 115 
under direct observation. At baseline, volunteers consumed a balanced diet (50% 116 
carbohydrate, 30% fat, 20% protein) matching their daily energy requirement calculated by 117 
basal metabolic rate multiplied by a physical activity level of 1.25 using the Schofield 118 
equation.
10
 To manipulate energy balance, baseline day 1 was followed by CR to 10% of 119 
normal energy requirement (mean of 222 ± SEM 4 kcal per day) for two days. After CR, 120 
participants were offered three substantial ad libitum buffet meals per day (20 MJ = 4777 121 
kcal) and additional snacks (16 MJ = 3821 kcal) between meals for two days. They were 122 
invited to eat freely; food consumption was covertly measured. Seven volunteers continued to 123 
9 
an additional day of FF (Figure S1). We performed PSG and measured metabolic, 124 
neuroendocrine, autonomic, and cognitive parameters at baseline, after CR, and FF, as 125 
detailed below. 126 
Polysomnography 127 
PSG for the assessment of sleep was performed during all nights using a SomnoScreen 128 
plus™ device (SOMNOmedics GmbH, Randesacker, Germany). Electrodes were attached to 129 
the scalp (Cz, C3, C4, O1, O2, A1, A2, Gnd) for electroencephalographic (EEG) recordings, 130 
above, below, and beside the eyes for horizontal and vertical electrooculogram, and on the 131 
chin for electromyogram. Recordings were scored offline by one investigator (S.M.S.) 132 
according to standard criteria by Rechtschaffen and Kales,
11
 and independently assessed by a 133 
second sleep lab analyst unaware of the study design and hypothesis. The following sleep 134 
parameters were determined: sleep period time (SPT, i.e. time interval between sleep onset 135 
and morning awakening), wake after sleep onset (WASO, i.e. duration of wake during SPT), 136 
total sleep time (TST, i.e. SPT minus WASO), time spent in sleep stages 1, 2, 3, 4, and rapid 137 
eye movement (REM) sleep (all in minutes and % of TST), as well as sustained sleep 138 
efficiency (TST divided by [time in bed minus sleep latency S1]). Furthermore, respiratory 139 
function as assessed by nasal air flow, chest excursions, and blood oxygen saturation (% 140 
SpO2) were analyzed for measures of apnea-hypopnea index (AHI, i.e. number of apnea + 141 
hypopnea per hour of TST), number of central apnea episodes during TST, central apnea 142 
index (i.e. number of central apnea episodes per hour of SPT), mean SpO2 (i.e. average value 143 
of complete SpO2 curve during TST), minimal SpO2 (minimum SpO2 during TST), and 144 
number of oxygen desaturations (i.e. a minimum decrease of 4% SpO2). All participants 145 
attended a pre-study overnight recording session with PSG to ensure that they had normal 146 
sleep architecture. 147 
10 
Analytical methods 148 
Plasma glucose, insulin, leptin, serum lipids, TSH, free thyroxin, GH, and cortisol, as well as 149 
routine biochemical and hematological assays were performed using standard commercially 150 
available assays. Concentrations of both total ghrelin and plasma orexin A were assessed 151 
using commercially available ELISA kits for humans (EZGRT-89K; Millipore, Billerica, MA 152 
and Uscn Life Science Inc., Wuhan, Hubei, China, respectively). The detection limit was 50 153 
pg/ml for total ghrelin and 4.83pg/mL for orexin A. 154 
Pulsatility analysis 155 
For overnight pulsatility analysis, we collected serum samples every 10 minutes from 156 
midnight to 06.00am, via a long line running from the participants to the adjacent room to 157 
avoid any interference with their sleep. Cluster analysis was used for the detection of discrete 158 
TSH, GH, and cortisol peaks.
12
 This computerized pulse algorithm is largely model-free and 159 
identifies statistically significant pulses in relation to dose-dependent measurement error in 160 
the hormone time series. For the present analysis a 2x1 test cluster configuration was used, 161 
two data points for the test nadir and one for the test peak, and a t-statistic of 2.0 for the up- 162 
and down-strokes, which minimizes both false positive and false negative peaks. The 163 
locations and widths of all significant concentration peaks were identified, the total number 164 
of peaks was counted, and the mean peak interval was calculated in minutes as well as peak 165 
height, width and area. In addition, valley mean and nadir, area under the curve, and total 166 
average value were calculated. 167 
Measurement of blood pressure and autonomic nervous system activation 168 
Blood pressure was measured using a wrist-type blood pressure monitor (OMRON 169 
Healthcare, Hamburg, Germany). Heart rate was measured continuously using a wireless 170 
11 
sensor applied to the chest wall (Actiheart, CamNtech Ltd, Cambridge, UK). This digitalizes 171 
the electrocardiogram signal and stores the R-R interval time-series from which heart rate can 172 
be calculated. Heart rate data was exported to a spreadsheet via Actiheart software (version 173 
4.0.116, CamNtech Ltd, Cambridge, UK). Sleep data collected by the PSG device was 174 
examined to determine a window of time (240 minutes) between 00:00 and 05:00 where each 175 
participant was asleep. Average heart rate while sleeping and on waking was calculated, and 176 
the difference between average asleep and average waking heart rate for each participant on 177 
each day was recorded. 178 
Mood, fatigue and cognition 179 







 As adequate sleep is necessary for the consolidation 181 
of memory,
17
 we tested whether concentration and the ability to retain information were 182 
affected by the study intervention. We measured alertness by reaction times and error rates in 183 
a computer-based vigilance performance test during the three study phases.
18
 Procedural 184 
memory formation was measured by finger tapping test
19
 and declarative memory formation 185 
by associate word learning paradigm.
20
 186 
Statistical analyses 187 
Unless specified otherwise, data are expressed as mean and standard error of the mean 188 
(SEM). Data were tested for normality using graphical and numerical methods (Shapiro-Wilk 189 
test). Data were compared by analysis of variance (ANOVA) with repeated measures to test 190 
for within-subjects changes. The within-subjects p-value was adjusted using the Greenhouse-191 
Geisser correction factor for lack of sphericity. Pairwise comparisons of the study phases 192 
were performed by two-sided Student’s t-test when appropriate. A p-value of 0.05 was 193 
considered significant after Bonferroni correction for multiple comparisons, i.e. by 194 
12 
multiplying the uncorrected p-value by the number of comparisons. For analyses of 195 
correlation between fasting hormones and sleep parameters, the non-parametric Spearman 196 
correlation test was used and repeated in sensitivity analyses excluding outliers. Data were 197 
analyzed using Stata software package (version 13.1, Stata Corp, College Station, TX). 198 
13 
RESULTS 199 
Rebound hyperphagia in response to caloric restriction 200 
Twelve adult males (mean age 24.2 ± SEM 1.3 years; mean BMI 23.1 ± 0.4kg/m
2
) were 201 
studied. Blood pressure, body composition, baseline biochemical and hematological 202 
parameters, and self-reported quality of sleep scores were within normal ranges (Table S1). 203 
Participants overconsumed when allowed to eat freely after two days of CR (mean 4500 ± 204 
165 kcal/day), to an extent that fully compensated for their energy deficit after two days of 205 
FF (Figure 1A). However, those individuals provided with ad libitum meals for a third day 206 
continued to overeat, eating 2000 kcal in excess on the third day (Figure 1A). 207 
Sleep architecture and sleep-associated respiratory parameters 208 
PSG recordings were performed at baseline, after CR and FF, and were visually scored by 209 
investigators blinded to the study design.
11
 At baseline, participants’ sleep architecture 210 
displayed a normal pattern when compared to reference data
21
 with approximately 50% of the 211 
night spent in stages 1 and 2, 25–30% spent in stages 3 and 4, and 20-25% spent in REM 212 
sleep. Total sleep time and sustained sleep efficiency were not affected by changes in energy 213 
balance (Table 1). Whilst there was no significant change in light sleep (stage 1 and 2) or 214 
REM sleep (Figure 1B), the duration of deep sleep (stage 3 and 4, or slow wave sleep [SWS]) 215 
increased by 18% in CR (Table 1). This change in deep sleep was entirely due to a marked 216 
increase in the duration of stage 4 sleep (p=0.02), which was fully reversed to baseline levels 217 
upon FF (p=0.008; Figure 1C). Whilst there was no significant difference in the number of 218 
awakenings with CR, the number of transitions between sleep stages was increased with 219 
borderline significance (105 at baseline vs. 119 in CR, p=0.06, Table 1). Changes in energy 220 
balance were followed by modest changes of the AHI, a marker of hypoventilation (p=0.05, 221 
14 
Table 1), but the AHI stayed below the threshold of sleep-disordered breathing (≥5 events per 222 
hour) throughout. 223 
Disordered sleep has been associated with impaired memory retention. Alertness, as 224 
measured by reaction times and error rates in a vigilance performance test, did not change 225 
during the study (data not shown). Sleep-dependent consolidation of procedural and 226 
declarative memory tested by a standard finger tapping task and paired associate word 227 
learning task were preserved during all study phases (Figure S2) and not modified by changes 228 
in energy balance. There was a discrete improvement in overall mood score as assessed by 229 
the Profile Of Mood States (POMS) questionnaire immediately upon FF compared to CR, but 230 
no significant changes in mood subdomains (Table S2). 231 
Pulsatile secretion of TSH, GH and cortisol 232 
Changes in energy balance can impact on the hypothalamic regulation of pituitary hormone 233 
synthesis and secretion which may in turn influence sleep architecture. We measured serum 234 
TSH, GH, and cortisol release (a marker of hypothalamo-pituitary adrenal axis activation) 235 
every 10 minutes for 6 hours overnight when participants were asleep as confirmed by PSG 236 
recordings. Mean hormone concentrations and parameters of pulsatile secretion were 237 
analyzed at baseline, after CR and FF using the pulse detection cluster algorithm (Table 2 and 238 
S3). Compared to baseline values, mean TSH concentrations, integrated total area under the 239 
curve (AUC), the peak pulse height and area, as well as valley means and nadirs were 240 
reduced after 48 hours of CR and increased to approximately 60% above baseline levels on 241 
FF (Figure 1D; Table 2). There were no differences in the number of pulses and pulse width. 242 
There was no change in the pulsatile secretion of GH from baseline to CR, while FF was 243 
associated with a decrease in mean GH concentrations and integrated total AUC compared to 244 
baseline and CR values (Figure 1E; Table 2). In conjunction, the interval between peaks was 245 
15 
longer during FF compared to baseline. No differences in cortisol secretion were seen as 246 
result of changes in energy balance (Figure 1F; Table S3). 247 
Autonomic nervous system activity 248 
To examine activation of the autonomic nervous system, we measured heart rate continuously 249 
throughout the study. The mean sleeping heart rate (predominantly influenced by 250 
parasympathetic tone) was unchanged after CR but increased by 5.0 beats per min with FF 251 
(p=0.04, Figure 2A). The increase in heart rate on waking (sleeping-to-waking heart rate 252 
increment; predominantly due to sympathetic nervous system [SNS] activation) increased 253 
from 5.8 to 9.4 beats per min in response to CR (p=0.05) and was reduced by 6.3 beats per 254 
min after 24 hours of FF (p<0.001, Figure 2B). Autonomic symptoms (predominantly 255 
adrenergic) were more prominent upon CR and decreased in FF (Table S4). 256 
Peripheral hormones and orexin 257 
Fasting plasma leptin decreased to 20% of baseline levels after 48 hours of CR (p<0.001), 258 
increasing to higher than baseline levels in FF (126%; p<0.001; Figure 3A). Fasting plasma 259 
insulin also decreased in CR (35%) and increased in FF (203% of baseline levels; both 260 
p≤0.002; Figure 3B). Fasting plasma glucose decreased by 1.2 mmol/l during CR and 261 
normalized upon FF (both p<0.001; Figure 3C). Glucose AUC over daytime (08:00 to 22:00) 262 
and over 24 hours (08:00 to 08:00) significantly decreased in CR compared to baseline and 263 
increased above baseline values in FF (all comparisons: p<0.001; data not shown). Plasma 264 
ghrelin levels exhibit diurnal variation, act as a short-term hunger signal peaking before meal 265 
initiation, and are affected by sleep restriction
22
 . Fasting total ghrelin did not change 266 
significantly with CR but decreased with FF in this study (p=0.03; Figure 3D); changes in 267 
ghrelin levels over 24 hours were not measured in our study. Plasma orexin increased in FF 268 
although this change was not statistically significant (p=0.06; Figure 3E). 269 
16 
We hypothesized that changes in peripheral hormones or in orexin might mediate the change 270 
in duration of stage 4 sleep seen with CR. Whilst there was no correlation between fasting 271 
leptin, insulin or total ghrelin and the duration of stage 4 sleep in CR (data not shown), 272 
plasma orexin levels correlated with specific sleep parameters after 48 hours of CR (Figure 273 
4A). The duration of stage 4 sleep correlated positively with orexin decline from baseline to 274 
CR (Spearman rho=0.83, p=0.01; Figure 4B). Although, the number of awakenings in CR did 275 
not correlate with plasma orexin (Figure 4C), they correlated negatively with orexin decline 276 
from baseline to CR (Spearman rho=-0.79, p=0.01; Figure 4D). A sensitivity analysis 277 
excluding one outlier confirmed the correlation of orexin decline in 48 hours from baseline to 278 
CR with the duration of stage 4 sleep in CR (Spearman rho=0.75, p=0.03) and the number of 279 
awakenings in CR (Spearman rho=-0.70, p=0.05; Figure S3). 280 
17 
DISCUSSION 281 
In this study we found that acute CR for two days significantly increased the duration of the 282 
deepest stage of sleep – stage 4 sleep. The effect of CR on stage 4 sleep was normalized with 283 
FF, which restored energy balance. Our findings provide direct evidence that energy balance 284 
and the sleep/wake cycle are tightly coupled in humans. Our findings align with a study from 285 
the 1970s which observed an increased duration of SWS (stages 3 and 4 together) and 286 
reduced REM sleep in males studied before and after four days of complete starvation 287 




Why might changes in energy balance lead to changes in the sleep/wake cycle? One 290 
possibility is that increasing the time spent in the deepest stage of sleep may allow for the 291 
conservation of energy resources in response to acute CR. Interestingly, positron emission 292 
tomography (PET) studies have found that cerebral glucose utilization rates decrease by 293 
~11% during non-REM sleep
24
 and even further (by ~44%) in SWS compared to 294 
wakefulness.
25
 The impact of CR on stage 4 sleep in humans is consistent with experiments 295 
in mammals and birds, where acute starvation can induce shallow torpor by almost 296 
continuous sleep.
26
 As animals mostly enter torpor and hibernation through SWS,
27
 an 297 
increase in SWS as seen in our study may represent part of the evolutionarily conserved 298 
physiological response to conserve energy in response to negative energy balance and the 299 
threat of starvation.  300 
Possible mechanisms linking energy balance and the regulation of the sleep/wake cycle may 301 
involve the adipocyte-derived hormone leptin which plays a pivotal role in mediating the 302 
physiological response to fasting/starvation.
28
 In our study, 48 hours of CR led to a marked 303 
decrease in leptin levels which rebounded in FF above baseline levels. Whilst a decline in 304 
18 
leptin has not previously been associated with changes in the sleep/wake cycle, direct 305 
evidence for the role of leptin in the regulation of the sleep/wake cycle comes from genetic 306 
disruption of leptin and the leptin receptor in rodents
29, 30
 which leads to increased total sleep 307 
time due to an increase in non-REM sleep, sleep fragmentation characterized by an elevated 308 
number of arousals and increased number of transitions between sleep stages. To date, very 309 
little is known about sleep architecture in rare severely obese patients with congenital leptin 310 
deficiency, a disorder which is often complicated by marked central and obstructive sleep 311 
apneas (own observations). 312 
Leptin and other peripheral signals of nutritional status may mediate effects on the 313 
sleep/wake cycle in part by acting on orexin neurons in the lateral hypothalamus, an 314 
important center for feeding and arousal. Targeted disruption of orexin and orexin receptors 315 
in mice leads to severely defective sleep/wake cycles.
31
 Furthermore, narcolepsy is 316 
characterized by low levels of orexin in the cerebrospinal fluid (CSF).
32
 For ethical reasons, 317 
we were unable to obtain CSF and measured plasma orexin A instead. We found that the 318 
decline in plasma orexin from baseline to CR was positively correlated with the duration of 319 
stage 4 sleep in CR and inversely correlated with the number of awakenings. This finding is 320 
intriguing but will require further investigation. We do not know whether, or how far, plasma 321 
orexin levels reflect orexin-mediated signaling in the brain. However, Strawn et al.,
33
 who 322 
performed simultaneous measurements of CSF and plasma orexin, found a strong correlation 323 
between CSF and plasma orexin levels (Spearman rho=0.81, p<0.0001), suggesting that 324 
plasma orexin levels may be used as an index of CSF orexin concentrations. 325 
In addition to the effects of CR on the sleep/wake cycle, we were able to demonstrate a trend 326 
towards reduced pulsatile secretion of TSH and impaired SNS activation. These observations 327 
in healthy volunteers are entirely consistent with studies in patients with genetic disruption of 328 
leptin signaling
34, 35
 and in obese people following weight loss
36
 (a state of partial leptin 329 
19 
deficiency). These physiological changes were predominantly mediated by falling leptin 330 
concentrations and could be reversed by concomitant leptin administration in previous 331 
studies.
34, 36
 We would have expected therefore, that two days of FF which restored energy 332 
balance, would restore leptin levels, pulsatile TSH secretion and autonomic function to 333 
baseline levels. However, intriguingly, we found that these parameters exceeded baseline 334 
values after two days of FF. The explanation for these findings is unclear. Such changes 335 
could contribute to an exaggerated compensatory response to CR, for example, by overeating. 336 
Some participants were studied during a third day of FF as we hypothesized that their food 337 
intake would return to baseline levels. Whilst ad libitum access to food may have promoted 338 
higher energy intake relative to energy requirement on this day, it is notable that energy 339 
intake on this third day remained excessive (mean 4293 ± 325 kcal/day), comparable to the 340 
first day of FF (p=0.29). These findings warrant further investigation and if replicated, may 341 
shed light on the physiological response to weight loss and the mechanisms that promote 342 
weight regain. 343 
In this study, we did not observe a significant change in GH pulses with CR in contrast to 344 
some, but not all, previous studies.
37
 As overnight sampling started at midnight in our study 345 
and the major GH pulse occurs within 30 minutes of sleep onset, changes in the sleep-onset 346 
GH pulse may not have been captured in some participants. Notably, we found that mean GH 347 
concentrations and integrated total area under the curve were significantly reduced during FF 348 
compared to baseline and CR. The pulsatile secretion of GH is predominantly the product of 349 
stimulatory GH-releasing hormone (GHRH)-expressing neurons and inhibitory somatostatin-350 
expressing neurons in the hypothalamus. Leptin treatment of rats food deprived for 48 hours 351 
increases somatostatin mRNA levels
38
 which would result in suppression of pulsatile GH 352 
secretion as seen in this study. It is recognized that pulsatile GH secretion is suppressed in 353 
obesity, but it is striking that we observed comparable levels of GH suppression after two 354 
20 
days of FF when participants were consuming excess calories but had restored energy 355 
balance. Variations in pulsatile release define the physiological actions of GH which is a 356 
critical mediator of insulin action and glucose homeostasis. We postulate that the suppression 357 
of GH secretion as seen in this study may reflect the physiological response to maintain 358 
glucose homeostasis in the light of excess caloric consumption. This hypothesis requires 359 
further testing in experimental studies. 360 
In conclusion, we have demonstrated for the first time in humans that acute manipulation of 361 
energy balance without change in body weight impacts on the sleep/wake cycle by 362 
specifically increasing the duration of the deepest stage of sleep – stage 4 sleep. Interestingly, 363 
previous studies have shown that the duration of stage 4 sleep is reduced in obese people 364 
without obstructive sleep apnea
39
 and that bidirectional changes in energy balance in mice 365 
can alter the sleep/wake cycle.
40
 366 
A number of investigators have examined the effects of changes in the sleep/wake cycle 367 
induced by sleep deprivation on energy homeostasis,
2, 9
 leptin levels, insulin sensitivity, and 368 
weight gain.
41
 Whilst the magnitude of metabolic effects seen varies depending on the 369 
duration of sleep deprivation, cumulatively these studies and ours demonstrate that energy 370 
balance and the sleep/wake cycle are tightly coupled in humans. These studies provide a 371 
mechanistic framework for investigating the well-recognized associations between obesity 372 
and sleep disorders and between sleep debt and obesity risk. 373 
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P values for overall comparison 


















0.87    
Total Sleep Time 
(TST), mins 
415.0 (11.4) 412.9 (14.6) 409.4 (10.2) 0.95    
Sustained sleep 
efficiency, % 
91.1 (1.9) 89.6 (2.9) 90.4 (2.2) 0.91    
Changes between 
sleep stages, no 
105.3 (4.6) 119.3 (6.7) 118.1 (7.7) 0.06 0.10 0.15 1.00 
Sleep stages        
Light sleep, mins 213.9 (9.4) 195.7 (10.2) 199.3 (8.7) 0.27    
Light sleep, %TST 51.6 (1.8) 47.6 (2.1) 48.9 (2.2) 0.15    
Stage 1, mins 33.5 (4.2) 31.5 (3.2) 30.3 (2.8) 0.68    
Stage 1, %TST 8.0 (1.0) 7.8 (0.8) 7.4 (0.7) 0.84    
Stage 2, mins 180.4 (7.4) 164.2 (10.4) 169.0 (8.3) 0.28    
Stage 2, %TST 43.6 (1.6) 39.8 (2.2) 41.4 (2.0) 0.14    
Deep sleep, mins 113.2 (7.9) 133.3 (8.5) 114.8 (7.7) 0.06 0.10 1.00 0.14 
Deep sleep, %TST 27.3 (1.6) 32.3 (1.7)
 
28.0 (1.7) 0.04 0.03 1.00 0.07 
Stage 3, mins 44.2 (4.6) 45.0 (4.7) 47.8 (5.9) 0.88    
Stage 3, %TST 10.5 (1.0) 10.7 (1.0) 11.9 (1.6) 0.69    
Stage 4, mins 69.0 (7.3) 88.3 (6.7) 67.0 (8.5) 0.007 0.02 1.00 0.008 
Stage 4, %TST 16.8 (1.8) 21.7 (1.8)
 
16.1 (1.9) 0.006 0.03 1.00 0.01 
REM sleep, mins 88.0 (7.0) 83.9 (6.6) 95.2 (5.5) 0.38    
REM sleep, %TST 21.1 (1.5) 20.1 (1.3) 23.2 (1.1) 0.15    
WASO, mins 38.8 (8.2) 44.7 (11.0) 41.4 (10.1) 0.92    
WASO, % SPT 8.7 (1.9) 10.1 (2.6) 9.2 (2.1) 0.92    




       
Mean oxygen 
saturation, % 
96.4 (0.3) 95.7 (0.7) 96.5 (0.2) 0.33    
Minimum oxygen 
saturation, % 
90.4 (1.9) 91.8 (1.0) 89.7 (1.9) 0.50    
Apnea-Hypopnea 
Index 
1.5 (0.5) 2.2 (0.7) 1.1 (0.2) 0.05 0.29 0.79 0.03 
Central apnea, no. 
episodes 
3.0 (1.1) 4.0 (1.8) 1.6 (0.5) 0.15    
Central apnea index, 
no. episodes/hour 
TST 
0.4 (0.2) 0.7 (0.4) 0.2 (0.1) 0.25    
25 
Footnotes: Sleep was recorded by polysomnography from 23.00 (lights out) to 07.00 (wake-up time) 388 
and classified into stages 1-4 and rapid eye movement (REM) sleep. All sleep parameters are reported 389 
as mean (standard error of the mean) and the duration of each sleep stage in minutes and relative to 390 
total sleep time (TST). The sustained sleep efficiency is TST divided by time in bed (TIB) minus 391 
sleep latency to stage 1. Sleep stage changes are expressed over the entire night. The duration of intra-392 
sleep wake (WASO, wake after sleep onset) is reported in minutes and relative to sleep period time 393 
(SPT, the time interval between sleep onset and morning awakening). Sleep data of the three study 394 
phases (baseline, BL, caloric restriction, CR, and free feeding, FF) were analyzed using analysis of 395 
variance (ANOVA) with repeated measures to test for within-subject changes. The within-subjects p-396 
value was adjusted using the Greenhouse-Geisser correction factor for lack of sphericity. Pairwise 397 
comparisons of the three study phases were performed by two-sided Student’s t-test when appropriate. 398 
A p-value of 0.05 was considered significant after Bonferroni correction for multiple comparisons. 399 
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P values for overall comparison 
Overall BL-CR BL-FF CR-FF 
Thyroid-stimulating hormone (TSH)     
Mean concentration, 
mU/l 
1.44 (0.25) 1.07 (0.18) 2.32 (0.35) <0.001 0.08 0.02 <0.001 
Area under the curve, 
mU/l x min 
514.4 (87.0) 386.8 (65.0) 842.8 (123.4) <0.001 0.07 0.01 <0.001 
Cluster analysis        
Number of peaks 3.25 (0.45) 3.75 (0.59) 3.13 (0.23) 0.81    
Interval between 
peaks, mins 
93.8 (22.0) 65.5 (5.3) 81.5 (10.1) 0.45    
Peak width, mins 67.1 (12.7) 47.1 (5.8) 54.8 (6.8) 0.47    
Peak height, mU/l 1.81 (0.31) 1.22 (0.21) 2.83 (0.48) <0.001 0.03 0.055 <0.001 
Peak area, 
mU/l x min 
20.7 (5.3) 8.4 (1.6) 30.5 (9.0) 0.01 0.06 0.84 0.006 
Valley mean, mU/l 1.37 (0.26) 1.01 (0.18) 2.18 (0.32) <0.001 0.09 0.02 <0.001 
Valley nadir, mU/l 1.20 (0.24) 0.91 (0.16) 1.89 (0.27) 0.002 0.16 0.03 <0.001 
Growth hormone (GH)     
Mean concentration, 
ng/ml 
3.13 (0.81) 3.52 (0.75) 1.08 (0.36) 0.003 1.00 0.001 <0.001 
Area under the curve, 
ng/ml x min 
1142.0 (296.1) 1267.7 (266.8) 393.1 (133.1) 0.003 1.00 0.001 <0.001 
Cluster analysis        
Number of peaks 2.00 (0.71) 2.25 (0.45) 1.88 (0.30) 0.60    
Interval between 
peaks, mins 
53.8 (4.6) 79.0 (7.5) 124.0 (26.6) 0.02 0.08 0.007 0.12 
Peak width, mins 97.0 (40.8) 133.2 (28.6) 127.1 (26.0) 0.30    
Peak height, ng/ml 9.92 (2.80) 28.53 (21.24) 3.83 (1.32) 0.06    
Peak area, 
ng/ml x min 
374.4 (155.0) 466.1 (216.0) 228.7 (144.8) 0.09    
Valley mean, ng/ml 4.29 (2.43) 1.89 (0.68) 0.71 (0.30) 0.40    
Valley nadir, ng/ml 3.79 (2.29) 1.63 (0.62) 0.60 (0.26) 0.44    
Footnotes: Data are reported as mean (standard error of the mean) for 8 participants. Pulsatility of 401 
thyroid-stimulating hormone (TSH) and growth hormone (GH) was assessed by cluster analysis. 402 
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Results of the three study phases (baseline, BL, caloric restriction, CR, and free feeding, FF) were 403 
analyzed using analysis of variance (ANOVA) with repeated measures after log-transformation of the 404 
variables to test for within-subject changes. The within-subjects p-value was adjusted using the 405 
Greenhouse-Geisser correction factor for lack of sphericity. Pairwise comparisons of the three study 406 
phases were performed by two-sided Student’s t-test when appropriate. A p-value of 0.05 was 407 
considered significant after Bonferroni correction for multiple comparisons. 408 
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FIGURE LEGENDS 409 
Figure 1 410 
(A): Energy intake was fixed to calculated 24-hour energy requirement on day 1 (baseline), was 411 
reduced to 10% of energy requirement on days 2 and 3 (caloric restriction, CR) and free feeding (FF) 412 
was allowed on days 4 and 5, with an additional day as part of an extended protocol in 7 individuals; 413 
to convert kilocalories (kcal) to mega-Joules (MJ), multiply by 0.0041868. (B-C): The duration of 414 
rapid eye movement (REM) sleep, light sleep (stages 1 + 2) and deep sleep (stages 3 + 4) was 415 
recorded using polysomnography at baseline, after 2 days of CR and after 2 days of FF. The 18% 416 
increase in the duration of deep sleep after CR (p=0.06) was entirely due to an increase in the duration 417 
of stage 4 sleep while stage 3 sleep was unaffected (C). Vertical bars represent the standard error of 418 
the mean (n = 12 participants). Durations of all sleep stages were analyzed using analysis of variance 419 
(ANOVA) with repeated measures to test for within-subject changes. The within-subjects p-value was 420 
adjusted using the Greenhouse-Geisser correction factor for lack of sphericity. Pairwise comparisons 421 
of the three study phases were performed by two-sided Student’s t-test when appropriate. A p-value of 422 
0.05 was considered significant after Bonferroni correction for multiple comparisons. D-F: Pulsatile 423 
secretion of thyroid-stimulating hormone (TSH) (D), growth hormone (GH) (E) and cortisol secretion 424 
(F) was measured in blood samples taken every 10 minutes from midnight until 6 am at baseline, after 425 
2 days of caloric restriction and after 2 days of free feeding. Vertical bars represent the standard error 426 
of the mean (n = 8 participants). 427 
Figure 2 428 
Mean sleeping heart rate (A) and the sleeping-to-waking heart rate increment (B) were measured 429 
every night in all 12 participants at baseline, during caloric restriction and free feeding. Vertical bars 430 
represent the standard error of the mean. Measurements were compared using analysis of variance 431 
(ANOVA) with repeated measures to test for within-subject changes. The within-subjects p-value was 432 
adjusted using the Greenhouse-Geisser correction factor for lack of sphericity. Pairwise comparisons 433 
of the three study phases were performed by two-sided Student’s t-test when appropriate. A p-value of 434 
29 
0.05 was considered significant after Bonferroni correction for multiple comparisons. 435 
Figure 3 436 
Fasting plasma levels of leptin (A, n=11), insulin (B, n=10), glucose (C, n=10), total ghrelin (D, n=9) 437 
and orexin A (E, n=10) were measured at baseline, after 48 hours of caloric restriction and after 48 438 
hours of free feeding. Vertical bars represent the standard error of the mean. Hormone levels were 439 
compared using analysis of variance (ANOVA) with repeated measures to test for within-subject 440 
changes. The within-subjects p-value was adjusted using the Greenhouse-Geisser correction factor for 441 
lack of sphericity. Pairwise comparisons of the three study phases were performed by two-sided 442 
Student’s t-test when appropriate. A p-value of 0.05 was considered significant after Bonferroni 443 
correction for multiple comparisons. 444 
Figure 4 445 
Correlation of plasma orexin A levels with sleep parameters after 48 hours of caloric restriction (CR) 446 
among 9 participants. The duration of stage 4 sleep correlated positively with orexin level in CR (A), 447 
as well as orexin decline from baseline to CR (B). There was no correlation between the number of 448 
awakenings and the absolute level of orexin in CR (C). The number of awakenings in CR correlated 449 
negatively with orexin decline from baseline to CR (D). A sensitivity analysis (SA) excluding one 450 
outlier confirmed the correlation of orexin decline in 48 hours from baseline to CR with the duration 451 
of stage 4 sleep in CR (SA of Panel B, Spearman rho=0.75, p=0.03) and the number of awakenings in 452 
CR (SA of Panel D, Spearman rho=-0.70, p=0.05). In this SA, there was no correlation between the 453 
plasma concentration of orexin in CR and the duration of sleep stage 4 (SA of Panel A, Spearman 454 
rho=0.48, p=0.23) or the number of awakenings in CR (SA of Panel C, Spearman rho=-0.59, p=0.12; 455 
Figure S3). 456 
